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 Abstract 
 Atypical or second-generation antipsychotics (SGAs) are a vital part of the management 
of many psychotic disorders, as well as behavioral and psychological symptoms. However, these 
medications have serious cardiometabolic complications, such as an increase in obesity, glucose 
intolerance, dyslipidemia, and hypertension, and can place the patient at serious risk for 
cardiovascular disease. The American Diabetes Association (ADA) and the American Psychiatric 
Association (APA) recommend clinical guidelines for metabolic screening, which requires the 
regular monitoring of patients treated with SGAs (ADA, 2004). The goal of this quality 
improvement project was to 1) implement a metabolic screening protocol based on ADA and 
APA guidelines for patients admitted to an acute psychiatric hospital who were treated with 
second-generation antipsychotics and 2) increase healthcare personnel awareness of metabolic 
monitoring guidelines and metabolic syndrome. This quality improvement project was 
implemented at an inpatient behavioral hospital in New England. A protocol for the monitoring 
of metabolic disturbances was placed in thirty patients’ medical charts, who were age eighteen 
and over, had been prescribed SGAs, and had been taking the medication daily since the 
admission to the hospital. Twenty-one psychiatric mental health staff members attended the 
educational interventions that were conducted by the author of the project 
 A retrospective chart review was performed post-intervention to assess guideline 
adherence by comparing the percentage of tests ordered pre-intervention versus the during the 
post-intervention period. Data were collected over a three-month period starting from November 
2018 until January 2019. The healthcare personnel awareness of metabolic monitoring guidelines 
and metabolic syndrome have been evaluated by a survey. After the intervention period, there 
were slight increases in the numbers of orders for hemoglobin A1c and lipid panel, but rates of 
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other baseline monitoring parameters (such as weight and blood pressure) remained the same or 
did not improve. The waist circumference was one of the indicators that had not been measured, 
even after the implementation of the screening protocol. 
 Keyword: atypical antipsychotics, metabolic syndrome, guidelines, monitoring, diabetes, 
dyslipidemia, cardiovascular disease 
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IMPLEMENTING A PROTOCOL TO MONITOR CARDIOMETABOLIC RISK IN 
PATIENTS PRESCRIBED ATYPICAL ANTIPSYCHOTICS 
   Introduction 
Second-generation antipsychotics (SGAs) medications brought new hope in the field of 
psychiatry, as they offered important benefits for people with mental health illness. Furthermore, 
they are associated with fewer complications of the extrapyramidal syndrome, tardive 
dyskinesia, and elevated prolactin, when compared with “typical antipsychotics” (Gill, Teong, 
Gee, Wen & Jawan, 2012; Newcomer & Haupt, 2006). However, soon after their introduction, 
several undesirable side effects, such as significant weight gain, insulin resistance, impaired 
glucose tolerance, and dyslipidemia, surfaced. All of these symptoms are associated with the 
development of metabolic syndrome, which is a key risk factor for cardiovascular disease (Ba, 
Su, Chen, Chen & Chang, 2013).  
Background 
Atypical Antipsychotics. In 1950, the introduction of the first typical antipsychotic, 
chlorpromazine (Thorazine) into clinical practice revolutionized the treatment of schizophrenia 
(De Hert, Vancampfort, Correll, Mersken, van Winkel & Mitchell, 2012). After a historic study 
completed by Elkes and Elkes in 1954, which was randomized and placebo-controlled, 
chlorpromazine started being accepted by psychiatrists all over the world. By the end of 1975, 
there were fifteen antipsychotic drugs available in the United States, and about forty worldwide 
(Ramachandraiah, Subramaniam, & Tancer, 2009). The arrival of clozapine, the first atypical 
antipsychotics, turned a new page for the treatment of schizophrenia. This medication was not 
associated with extrapyramidal symptoms seen with typical antipsychotics. Clozapine became 
the model for a new class of atypical antipsychotic drugs, and thirty years later, risperidone was 
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created, which became the most commonly prescribed antipsychotic medication in the United 
States (Perese, 2012).   
Atypical antipsychotics are a vital part of medical management for a wide range of 
psychiatric disorders and behavioral disturbances. In addition to schizophrenia, atypical 
antipsychotics are often prescribed for the treatment of aggressive and disruptive behavior, 
bipolar mania and depression, unipolar severe depression that does not respond to standard 
antidepressant treatment, and Tourette’s syndrome. Nowadays, atypical antipsychotics are widely 
used, especially among children and adolescents (De Hert et al., 2012) and their off-label usage 
is also seen in many older patients suffering from dementia.  
                  Antipsychotics are divided into first-generation “typical” drugs that treat the positive, 
but not the negative, symptoms associated with psychosis (schizophrenia), and second-
generation agents, called atypical antipsychotics, which have fewer extrapyramidal symptoms 
(EPS) and tardive dyskinesia (TD) symptoms, when compared with the typical antipsychotics. 
Although atypical antipsychotics do not exhibit the side effects of the typical antipsychotics to 
the same degree, some of them have a tendency to cause weight gain, as well as cardiovascular 
and metabolic changes, and insulin resistance (De Hert et al., 2012). Patients with the first 
episode of schizophrenia, those who are antipsychotic drug-naïve, children, and adolescents are 
especially at risk for developing metabolic disturbances and obesity (De Hert et al., 2012). 
Atypical or second-generation antipsychotics (SGAs) contribute significantly to 
cardiometabolic and endocrine adverse symptoms constituting metabolic syndrome (MetS) 
(Newcomer & Haupt 2005). Metabolic syndrome is a group of risk factors, including 
dysglycemia, hypertension, dyslipidemia, and central obesity, that is associated with the 
development of cardiovascular disease (Alberti, Zimmet, & Shaw, 2005). Metabolic syndrome is 
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a leading cause of increased morbidity and mortality in patients who also suffer from 
schizophrenia (Riordan, Antonini, & Murphy, 2011). Metabolic syndrome has substantial cost 
implications for society; however, ongoing patient monitoring of simple laboratory and clinical 
measures can help decrease adverse effects, improve patients’ quality of life, and reduce 
healthcare costs. 
With the development and introduction of the atypical antipsychotic medications, a new 
era in the treatment of psychiatric disorders began. The first in this class, clozapine (Clozaril), 
fell quickly out of favor in the beginning due to drug-induced agranulocytosis. During the 1990s, 
olanzapine (Zyprexa), risperidone (Risperdal), and quetiapine (Seroquel) were introduced, and 
ziprasidone (Geodon) and aripiprazole (Abilify) were introduced ten years later, during the 
2000s. Paliperidone (Invega) was FDA -approved in 2006. Atypical antipsychotics soon 
constituted the first-line treatment for schizophrenia, due to the decreased incidence of 
extrapyramidal side effects (EPS) (Farah, 2005), tardive dyskinesia (TD), and the absence of 
prolactin elevation (Seeman, 2002).     
Since their introduction, atypical antipsychotics have been prone to both on-label and off-
label usage due to their many notable benefits. Despite their important role in the treatment of 
many psychiatric disorders, it was noted that these agents have the potential to cause significant 
metabolic disturbances, such as an increase in obesity, glucose intolerance, dyslipidemia and 
hypertension (Correll, Frederickson, Kane, & Manu 2007).  
It is still uncertain why some of the atypical antipsychotics carry higher risks for 
metabolic syndrome than others. Apparently, the cardiometabolic complications vary with 
respect to receptor pharmacology that suggests common pathophysiological mechanisms. For 
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example, olanzapine and clozapine, two drugs that are known to cause the largest weight gain, 
have a high affinity for 5-HT2C and histamine H1 receptors (Reynolds & Kirk, 2010).  
In 2004, the American Diabetes Association (ADA), the American Psychiatric 
Association (APA), the American Association of Clinical Endocrinologists (AACE), and the 
North American Association of the Study of Obesity (NAASO) acknowledged the correlation 
between atypical antipsychotics and the development of metabolic syndrome, and also provided 
recommendations for the use and monitoring of these agents (ADA, 2004). The report 
emphasized that prescribers should evaluate the risks and benefits of prescribing specific atypical 
antipsychotics. ADA and APA statement recommended routine monitoring frequencies for the 
weight (BMI), waist circumference, blood pressure (BP), fasting plasma glucose, and fasting 
lipid profile (ADA, 2004). 
Metabolic Syndrome. The criteria for metabolic syndrome, which is sometimes referred to as 
syndrome X, are diverse and a standard definition does not exist. The World Health Organization 
(WHO), the European Group for the Study of Insulin Resistance, and the National Cholesterol 
Education Program Adult Treatment Panel (NCEP ATP) III agree that the base components of 
metabolic syndrome are obesity, insulin resistance, dyslipidemia, and hypertension (Riordan et 
al., 2011). The International Diabetes Federation (IDF) proposed a set of metabolic syndrome 
criteria that include weight gain and hypertriglyceridemia, along with increased glucose and low-
density lipoprotein cholesterol levels. Central obesity is a major component among the proposed 
sets of symptoms, with different waist circumferences for different ethnicity groups, along with 
triglyceride levels higher than 150 mg/dl; HDL cholesterol lower than 40 mg/dl in men or lower 
than 50 mg/dl in women; systolic blood pressure higher than 130 mmHg and diastolic blood 
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pressure higher than 85 mmHg; and fasting plasma glucose higher than 100 mg/dl (Alberti 
Zimmet & Shaw 2005). The IDF metabolic syndrome criteria are shown in Table 1. 
The National Institute of Health (NIH) (2001) defined metabolic syndrome as “a 
combination of risk factors that puts the individual at risk for cardiovascular disease” (NIH, 
2001). Overwhelming evidence shows that metabolic syndrome can increase the risk of 
developing type 2 diabetes mellitus and can increase both the ten-year risk of coronary heart 
disease, three-to-six-fold (Bobes et al., 2007; De Hert et al., 2012), and the mortality rate from 
cardiovascular disease (Daumit, 2008). Prospective longitudinal studies reveal that the 
occurrence of metabolic adverse effects (such as weight gain, hyperglycemia, hypertension, and 
dyslipidemia) in patients increase significantly after the patient’s initial exposure to atypical 
antipsychotic medications (De Hert et al., 2012; Foley & Morley, 2011).  
Patients with major mental illness have the same modifiable risk factors for 
cardiovascular disease and developing metabolic syndrome as the general population such as 
smoking, unhealthy lifestyles, diet, and a sedentary lifestyle or lack of physical activity (Hasnain 
et al., 2009). However, some researchers suggested that atypical antipsychotic drugs induce 
weight gain that is responsible for impaired glucose metabolism, which is independent of 
adiposity, and glucose and lipid metabolism abnormalities may occur without weight gain 
(Hasnain et al., 2009). 
Impaired glucose metabolism and insulin resistance were the first abnormalities to be 
reported in patients with schizophrenia and bipolar disorders receiving atypical antipsychotic 
medications; however, weight gain is the most noticeable and distressing syndrome among 
patients. Different atypical antipsychotics are associated with varying effects on body weight, 
plasma glucose, and lipid levels. Overwhelming evidence shows that an increase in adipose 
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tissue is associated with a decrease in insulin sensitivity, which contributes to increases in plasma 
glucose and lipids and a higher risk for diabetes and cardiovascular diseases. 
 In 2006, John Newcomer and Dan Haupt reviewed evidence showing that treatment with 
antipsychotic medications (particularly with atypical antipsychotics) can be associated with 
weight gain, insulin resistance, hyperglycemia, dyslipidemia, and diabetes (Newcomer & Haupt, 
2006). The authors identified relevant publications through a search of MEDLINE from the years 
1975 to 2006. They found that some of the atypical antipsychotics are associated with moderate 
increases in body weight (amisulpride, ziprasidone, and aripiprazole); however, others have a 
significant risk for weight gain and disordered glucose and lipid metabolism (olanzapine and 
clozapine) (Newcomer & Haupt, 2006). The SGAs side effects are shown in Table 2. 
Differential metabolic profiles of atypical antipsychotics were also suggested by other 
researchers. The researchers involved in the Clinical Antipsychotic Trials in Intervention 
Effectiveness (CATIE) have shown a significant increase in the prevalence of metabolic 
syndrome for olanzapine and quetiapine over three months but a decrease for ziprasidone (Meyer 
et al., 2008). Olanzapine was associated with the largest mean increase in waist circumference, 
subsequent weight gain, and significant changes in fasting triglycerides (Meyer et al., 2008).    
Saddichha and colleagues conducted an extensive prospective randomized, double-blind 
controlled study, including the measurement of waist circumference, blood pressure, triglyceride, 
high-density lipoproteins, and fasting blood sugar levels on patients with first-episode 
schizophrenia who received either first-generation haloperidol, or second-generation olanzapine 
or risperidone (Saddichha, Manjunath., Ameen & Akhtar, 2008). The analysis shows that the 
prevalence of MetS in a patient with schizophrenia was at least five times higher when compared 
to the matched healthy control group. The highest prevalence of MetS had olanzapine at twenty 
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to twenty-five percent, followed by risperidone at nine to twenty-four percent, and haloperidol at 
zero to three percent (Saddichha et al., 2008).        
The most noticeable sign of MetSyn is weight gain, and atypical antipsychotics have been 
frequently cited for causing it (Lieberman et al., 2004). Long-term treatment with these agents 
can cause weight gain from about one kilogram over one year with aripiprazole and ziprasidone; 
two to three kilograms with quetiapine and risperidone; and over six kilograms with olanzapine 
(Newcomer et al., 2006). Kahn and colleagues conducted a twelve-month open randomized 
clinical trial for patients with the first episode of schizophrenia treated with second-generation 
antipsychotic drugs (amisulpride, olanzapine, quetiapine, and ziprasidone) and found that there 
was notable weight gain, from 4.8 kg to 9.7 kg (Kahn et al., 2008). 
Insulin Resistance. Another concern about treatment with atypical antipsychotics is an increased 
risk of insulin resistance, hyperglycemia, and diabetes. A population-based study associated with 
an increased risk of type 2 diabetes mellitus in patients treated with atypical antipsychotics 
versus control patients without schizophrenia was conducted by Liao and colleague (Liao et al., 
2011). Authors reported that in the Cox models, significance adjusted hazard ratios (HR) 
associated with second-generation antipsychotics were 1.82 (95% confidence interval (CI) 1.30-
2.55) for diabetes and 1.41 (95% CI 1.09-1.83) for hyperlipidemia. A ten-year nationwide 
population-based prospective cohort study using a nationwide database with a large sample size 
including patients with bipolar disorders (BD), major depressive disorder, and schizophrenia 
showed an increase in metabolic disturbances that required initiation of diabetic and 
hyperlipidemia medications, especially among patients with BD (HR of 1.506, 95% CI: 1.107-
2.047) and schizophrenia (HR of 1.154, 95% CI: 1.002-1.329). 
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Problem Statement 
Atypical, or second-generation antipsychotics, can lead to serious cardio-metabolic disturbances, 
such as weight gain, dyslipidemia, and glucose intolerance, and can increase the mortality from 
cardiovascular disease. Baseline and ongoing monitoring are recommended for patients 
prescribed atypical antipsychotic medications in order to reduce the risk and ensure the well-
being of the patients. 
Organizational “Gap” Analysis of Project Site 
The goal of this project was to help identify the existing gap between the current practice 
of tests ordered in patients treated with SGAs, according to guideline recommendations, and to 
propose corrective action, with the end goal of implementing a protocol for metabolic syndrome 
monitoring. Donabedian’s conceptual models align well with the gap analysis and can serve as a 
framework for this project (Davis-Ajami, Costa & Kulik, 2014). Donabedian’s structure, process, 
and outcomes framework incorporate clinical and patient factors as well as system and 
institutional factors and serves as a link between care intervention, outcomes and effectiveness 
evaluations (Davis-Ajami et al., 2014).  
All atypical antipsychotics provide a warning about the risk of hyperglycemia and 
diabetes, as well as suggestions for regular monitoring of plasma glucose; however, very little 
data is available about adherence to these monitoring recommendations (US Food and Drug 
Administration, 2004). Inconsistencies with assessing the patient and the lack of adherence to 
monitoring for cardio-metabolic syndrome symptoms can also be problematic. The research 
suggests that in some clinics, less than one-third of the patients prescribed atypical antipsychotics 
undergo any blood glucose or lipid testing (Riordan et al., 2011). In addition to psychotic 
disorders, atypical antipsychotics are often prescribed off-label for the treatment of aggressive 
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and disruptive behaviors in different age groups by primary care providers who have limited 
knowledge about guidelines and monitoring requirements (Mitchell, Delaffon, Vancampfort, 
Correll & De Hert, 2011).  
Things are not any different at the project site. There is no available protocol for 
metabolic syndrome monitoring for patients who are being prescribed atypical antipsychotics; 
furthermore, prescribers do not adhere to guidelines for monitoring their patients as gap and 
SWOT analyses showed as you can see in Table 3. 
Review of the Literature  
The focus of this literature review was on metabolic complications that arise when 
atypical antipsychotics were administered, and guidelines for the monitoring of metabolic risk in 
people treated with these agents. Databases and websites that have been reviewed included 
PubMed, CINAHL, Cochrane Reports, Agency for Healthcare Research and Quality (AHRQ), 
and Web of Science. Search terms used included: atypical antipsychotics, psychiatric disorders, 
metabolic syndrome, cardiovascular risk, and guidelines. Inclusion criteria consisted of full-text 
articles published between 2000 and 2017 in the English language, concerning adults greater 
than eighteen years old. The initial search using just two keywords, SGAs, and MetSyn, yielded 
14,013 articles and guidelines. The search was further narrowed down to 242 publications by 
adding more keywords: guidelines, monitoring, diabetes, dyslipidemia, and cardiovascular 
diseases. The final search yielded forty-three articles and was performed by applying filters for 
age (above eighteen years old), language (English), and articles that were published in the past 
fifteen years.  
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Level 1 Evidence: Case Reports and Uncontrolled Observational Studies 
Evidence from case reports, prospective observational studies, retrospective database 
analyses, and controlled experimental studies suggest a strong link between atypical 
antipsychotics and adverse effects on glucose and lipid metabolism (Newcomer & Haupt, 2006). 
The majority of metabolic complications occur within the first six months after the initiation of 
treatment and include substantial weight gain, hyperglycemia, metabolic acidosis, ketosis, and 
diabetic ketoacidosis-related deaths. All these complications are more frequently associated with 
clozapine (Clozaril) (Koller & Doraiswamy, 2001), olanzapine (Koller, Schneider, Bennett & 
Dubitsky, 2002), and risperidone treatments (Koller, Cross, Doraiswamy & Schneider, 2003).  
There is little evidence that ziprasidone, amisulpride, and aripiprazole cause such adverse effects.  
A case report for olanzapine, risperidone, and quetiapine, that included data from the 
Federal Drug Administration (FDA) and Med Watch Drug Surveillance System, from 1999 to 
2001 and 2002, reported high rates and incidents of diabetic ketoacidosis, hyperglycemia, 
metabolic acidosis, pancreatitis, and new-onset diabetes associated with use of these atypical 
antipsychotic medications (Koller et al., 2001, 2002,2003).  
Level 2 Evidence: Observational database Analyses 
Two-thirds of observational database analyses studies report a connection between some 
atypical antipsychotic medications and weight gain, as well as a consequential increased risk for 
diabetes mellitus (Newcomer & Haupt, 2006). Newcomer and colleagues conducted a 
metanalytic review of the relevant literature in an effort to determine the relationship between 
antipsychotic treatment and risk for diabetes (Newcomer & Haupt, 2006). They searched 
MEDLINE and Current Contents from January 1990 to September 2004 for all relevant 
publications on studies using atypical antipsychotics for the treatment of different psychiatric 
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disorders. Their analysis consistently shows that clozapine and olanzapine are the two 
antipsychotics that cause an increased risk for diabetes most often.  
Level 3 Evidence: Controlled Experimental Studies and Randomized Clinical Trials 
Long-term schizophrenia trials using different atypical antipsychotics demonstrated 
statistically significant increases in fasting glucose and insulin levels with olanzapine and 
clozapine therapy and no significant changes with ziprasidone and aripiprazole (Pigott, Carson, 
Saha, Torbeyns, Stock, & Ingenito, 2003; Reynolds & Kirk,2002). In an eight-week randomized, 
double-blind trial of 157 patients with schizophrenia treated with clozapine, olanzapine, 
risperidone, or haloperidol conducted by Lindenmayer and colleagues, the authors found that at 
the end of week six, there was a significant increase in mean glucose and cholesterol levels in 
patients who received olanzapine, and at the end of the eight-week period, there were increases 
in glucose and cholesterol levels in patients who received clozapine (Lindenmayer et al., 2003). 
Monitoring Guidelines 
The screening and monitoring of metabolic complications when atypical antipsychotics 
were administered became a focus for many researchers, and different national and international 
organizations have developed their own guidelines for monitoring and managing the risk of these 
complications. The guidelines, defined as “systematically developed statements to assist 
practitioner and patient decisions about appropriate healthcare for specific clinical 
circumstances” (Institute of Medicine, 1992), is considered a good option for translating research 
into clinical practice (De Hert et al., 2011). 
In November 2003, the ADA, the APA, the AACE, and the NAASO reviewed all 
available data on the metabolic effects of atypical antipsychotic medications and established a 
strong link between their use and the risk of developing the metabolic syndrome during their 
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conference (Riordan et al., 2011). The majority recommended a baseline screening and ongoing 
monitoring of metabolic status and cardiovascular risk factors in patients treated with second-
generation antipsychotic medications. The baseline screening measures when the atypical 
antipsychotic medication is initiated and includes body mass index (BMI), waist circumference, 
blood pressure, fasting plasma glucose, fasting lipid profile, and a personal and family history of 
metabolic syndrome disturbances. If the patient has one or more of the following abnormalities, 
initiation of the treatment is recommended: overweight (BMI 25.0-29.9), obesity (BMI>30), 
prediabetes (fasting plasma glucose (FPG) 120-125 mg/dl), diabetes (fasting plasma glucose 
>126 mg/dl), hypertension (blood pressure (BP)>140/90 mmHg), or dyslipidemia (Rabia, 2007).  
The consensus also recommended ongoing monitoring for factors such as personal 
history, weight (BMI), waist circumference, BP, FPG, and fasting lipid profile at baseline, four 
weeks, eight weeks, twelve weeks, quarterly, annually, and every five years (Riordan et al., 
2011). The ongoing monitoring protocol is shown in Table 4. This guideline is based on lifestyle 
management and is very easy to use in primary care settings. The metabolic syndrome time 
monitoring tool that the guideline proposed is an important instrument for the management of 
metabolic disturbances, and the most valuable evidence-based resource for this DNP project.  
From the review of the literature, it is obvious that there are significant research and 
many practice guidelines for managing metabolic syndrome and metabolic complications. In 
2011, De Hert and colleagues published a systematic review and quality assessment of all 
guidelines and recommendations for monitoring a cardiovascular risk in patients with 
schizophrenia published between 2000 and 2010, using the Appraisal of Guidelines for research 
and evaluation (AGREE) (De Hert et al., 2011). From a total of fifty-four guidelines that the 
authors found, eighteen were identified for AGREE evaluation. All the guidelines covered 
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diabetes and cardiovascular disease risk in patients treated with antipsychotics. All guidelines 
included monitoring weight, body mass index (BMI), and fasting glucose; some included 
measurements of waist circumference and assessment of fasting lipids; and the more recent 
guidelines were more detailed and included evaluations of personal and family history, and 
cardiovascular risk factors (De Hert et al., 2011). Based on their review of the guidelines, the 
authors concluded that all patients with schizophrenia treated with SGAs should be under the 
active care of a medical physician, and they proposed a monitoring protocol. The protocol is 
shown in Table 4. 
Despite the recommendations, there is an inconsistency in the implementation of these 
guidelines, and adherence to them by healthcare providers (Riordan et al., 2011). 
Sankaranarayanan, A. & Castle, D. (2012) found that diabetes and dyslipidemia screening among 
patients treated with atypical antipsychotic drugs was low and did not improve after the 
recommendations from the ADA and APA. They reported that the best rates are around sixty 
percent coverage for the routine monitoring of blood glucose and lipids, and fifty-four percent 
for weight management.      
When left untreated, metabolic syndrome can lead to serious cardiovascular 
complications and death. The researchers found that the risk for coronary heart disease and 
stroke was tripled, and cardiovascular mortality rates increase significantly among individuals 
diagnosed with metabolic syndrome (Lieberman et al., 2004). Despite ADA, APA, AACE, and 
NAASO recommendations for screening and the ongoing monitoring of patients receiving 
atypical antipsychotics, many healthcare providers do not consistently adhere to these guidelines 
(Cohn & Sernyak, 2013).     
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Theoretical Framework/Evidence-Based Practice Model 
The project was based on the Donabedian conceptual framework for the examination of 
health services and the evaluation of the quality of health care (Fig.1). Avedis Donabedian was a 
professor and a healthcare researcher at the University of Michigan, and he proposed that an 
improvement in the structure of care should lead to an improvement in clinical processes that 
would improve patient outcomes. His article “Evaluating the Quality of Medical Care,” 
published 1966, became the foundation of his body of work on the theory and practice of the 
quality assurance of health services research. During his career, he developed methods to 
measure the quality of healthcare, and in his landmark 1966 article, Donabedian suggests a triad 
of structure, process, and outcome to evaluate the quality of healthcare (Ayanian, 2016). He 
defined the structure as all factors delivered to the patients that directly affect their care, 
including the facility, equipment, human resources, training and qualification of the providers. 
The processes are technical processes or interpersonal processes, and they comprise the sum of 
all actions in terms of the way in which care is delivered. Lastly, the outcome is the effects on 
patients, changes to health status or knowledge, and patient satisfaction (Donabedian, 1966).  
The structure, according to Donabedian, includes all the factors that affect the context in 
which care is delivered. This includes the facility, equipment, and human resources 
(psychiatrists, mental health nurse practitioners, and nurses), as well as organizational 
characteristics such as staff training and Joint Commission accreditation of the hospital. Using 
Donabedian’s conceptualization of quality of care, the present quality improvement project 
operationalized structure as hospital assets of psychiatrists, mental health care nurse 
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practitioners, and staff nurses’ knowledge about metabolic syndrome monitoring guidelines and 
recommendations. 
The process is the sum of all actions that make up healthcare. These include diagnosis, 
treatment, patient educations, and how care is delivered.  The protocol for monitoring metabolic 
syndrome abnormalities that this quality improvement project proposes is a part of the process 
that will improve patients’ outcome. Early recognition and the reduction of metabolic syndrome 
abnormality in patients treated with SGAs by screening and testing will improve their quality of 
life. 
Goals, Objectives and Expected Outcomes 
The purpose of this quality improvement project was to provide information on metabolic 
screening and to implement a protocol for the metabolic screening and monitoring of patients 
who are prescribed second-generation antipsychotics, as well as to assess whether this protocol is 
followed up by the prescribers, which was evidenced by increased rates of relevant testing. 
The objectives: 
1. Increased awareness of metabolic screening guidelines among mental health care staff. 
            2. Increase psychiatric prescribers’ readiness to implement a metabolic screening protocol 
based on guidelines as evidenced by the increased number of testing for HgA1c, fasting lipids, 
blood pressure, and waist circumference.  
The quality improvement project followed Donabedian quality improvement conceptual 
model as a framework (Fig.1). The DNP student utilized the hospital base and organization, and 
mental health staff (structure) to implement a screening metabolic protocol (process) in order to 
improve the patient’s health and clinical outcomes. 
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 Methods 
This quality improvement practice project aimed to increase the awareness by the 
psychiatric mental health providers and staff about metabolic complications with SGAs and their 
adherence to guidelines for metabolic monitoring of patients on atypical antipsychotics. During 
the project the following took place: 
 An informational session was provided to twenty-one mental health care prescribers and 
nursing staff who were involved in the monitoring and management of selected patients treated 
with SGA, as an educational component to introduce the APA and the ADA guideline of 
metabolic syndrome testing, and to identify the project objective (Appendix A). 
Each psychiatrist, PMHNP and staff nurse was encouraged to take a survey to determine 
their knowledge of existing guidelines for metabolic syndrome monitoring, self-efficacy, and 
possible barriers to following up the guideline (Appendix B). 
The protocol (Appendix C) was then placed in charts (the hospital uses paper charts) of 
the patients admitted to the institution between September 30, 2018, and December 31, 2018 
with a goal of including up to thirty psychiatric patients who were adults (age eighteen and 
greater) and were treated with atypical antipsychotic medications.       
     Project Site and Population 
This project was conducted at a behavioral health hospital in New England, a 120-bed 
inpatient hospital with three adult units, one geriatric unit, and one adolescent unit that mandates 
twenty-four-hour coverage by board-certified psychiatrists. The hospital serves eighty-four 
towns and cities. These are the only counties in the nation where Portuguese Americans make up 
the plurality of the population including the Portuguese Americans, the Brazilians Americans, 
and the Portuguese Cape Verdean population. The region is home to approximately one million 
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people residing in over 1,300 square miles. The area is ethnically and linguistically diverse with 
Portuguese speakers well represented. Most mental health services are provided through health 
insurance, such as Medicaid or private insurance. Despite the fact that more than sixty-two 
percent of the population is employed, many of the patients of Portuguese and Brazilians descent 
served by this hospital are poor or homeless (US Census). Many of them have mental health 
issues ranging from schizophrenia and bipolar disorders to PTSD, alcohol and substance abuse.   
                                                         Implementation Plan 
At the pre-implementation phase, the DNP student offered a 45-minute educational 
session to nine psychiatric providers and twelve staff nurses working with the selected patients, 
to review the ADA/APA guideline recommendations for metabolic screening in patients treated 
with SGAs. Information was provided about the metabolic complications, the importance of 
screening, and the proposed screening protocol. By the end of the session, health care personnel 
were invited to take a survey with three closed-ended questions and two open-ended questions to 
test participants’ knowledge about guidelines for the monitoring of metabolic syndrome in a 
patient treated with SGAs and anticipated barriers.  
The author of the project created a metabolic monitoring protocol based on the 
recommendations made by the American Diabetic Association (ADA), American Psychiatric 
Association (APA), American Association of Clinical Endocrinologists (AACE), and North 
American Association of the Study of Obesity (NAASO). This protocol was placed during the 
implementation phase in the thirty paper charts of patients aged eighteen years old and above, 
who had been on at least one scheduled atypical antipsychotic.  
The protocol was placed in the thirty selected patients’ charts during the time period from 
October 25, 2018, until December 30, 2018. The review of the medical records of those patients 
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who have had the protocol was carried out on a weekly basis between December 15, 2018, and 
January 31, 2019, by the DNP student. Based on national and international guidelines, the DNP 
student used the following standards for a monitor for metabolic disturbances in the selected 
patients’ charts: 
1. All patients on atypical antipsychotics should have their BMI, waist circumference, 
blood pressure, lipid level, and fasting or random glucose level tested at baseline and at 
three, six, and twelve months.  
2. Results are abnormal and should be acted on if the following is noted in a patient: 
- BMI ≥30 kg/m² 
- waist circumference ≥94 cm for male and ≥80 cm for female 
- total cholesterol ≥240 mg/dl (4.6 mmol/l) 
- triglycerides ≥ 150 mg/dl (1.7 mmol/l) 
- high-density lipoprotein cholesterol < 40 mg/dl (1.03 mmol/l) for males and < 
50mg/dl (1.29 mmol/l) for females 
- systolic blood pressure ≥130 mmHg 
- diastolic blood pressure ≥85 mmHg 
- fasting plasma glucose ≥100 mg/dl (5.6 mmol/l) 
- random plasma glucose ≥110 mg/dl (6.6 mmol/l). 
3. All patients with abnormal results should be referred to the medical clinical specialist. 
 Charts of the patient who were prescribed SGAs were identified from the three adult 
inpatient units between September 1, 2018, and November 30, 2018. A chart review was 
performed by the DNP student (who is employed as a nurse at the facility), starting in September 
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2018, to identify all patients over the age of eighteen receiving atypical antipsychotics, in order 
to identify patients for monitoring.  
A list of all patients’ charts (who were eighteen years and older) admitted to the three 
adult units at the Behavioral Hospital and prescribed atypical antipsychotics was created at the 
beginning of the implementation phase. Every eligible patient’s chart was assigned a number and 
this number was used for identification during the implementation of the screening protocol. The 
list of the charts and their assigned numbers were kept in a secure location, in a locked drawer, 
that only the author of the project had access to, in order to protect patients’ information in 
accordance with HIPPA (US Department of Health and Human Services, 2003). Table 5 shows a 
working data sheet that was created by the DNP nurse student for the collection of the 
information.  
During the implementation phase, the screening metabolic monitoring protocol was 
placed in the medical record of the thirty eligible patients’ charts, in the physician orders section. 
The number of parameters completed at baseline (weight, BMP, waist circumference, blood 
pressure, fasting glucose level, and fasting lipid levels) was recorded. During the post-
implementation phase, after the screening protocol was placed in the patient’s chart, the number 
of ordered tests (HgA1c, lipids) was recorded along with weight, BMI, blood pressure, and waist 
circumference.  
Ethical Considerations 
All participants were protected by the Health Insurance Portability and Accountability 
Act of 1996 (HIPAA), which, among other guarantees, protects the privacy of patients’ health 
information (Modifications to the HIPAA Privacy, Security, Enforcement, and Breach 
Notification Rules, 2013).  Additionally, the DNP student carefully conducted this project 
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following the Standards of Care for practice.  All information collected as part of evaluating the 
impact of this project did not include any potential patient identifiers. The risk to patients 
participating in this project as reviewing their charts was no different from the risks of patients 
receiving standard psychiatric care.   
Participant confidentiality was assured by coding the participants using individual 
identification numbers and keeping this list of participants with identifying numbers in locked 
filing cabinets in the hospital, only accessible to the DNP student. All electronic files containing 
identifiable information were password protected to prevent access by unauthorized users, and 
only the DNP student had access to the passwords.   
This project consisted of implementing a protocol for metabolic syndrome monitoring of 
patients receiving SGAs and their charts review, and there were no risks to the participant; 
patients, and mental health prescribers, and nursing staff. The health care providers had a choice 
to participate in the explanatory meeting about the purpose of this quality improvement project. 
The patients’ charts review was performed by the DNP student and the identity of patients was 
not shared with administration. 
The project was reviewed and approved by The New England Behavioral Health 
administration and management, and by Human Research Protection Office at the University of 
Massachusetts Amherst. (Appendix D). 
Data Analysis 
Planning activities for this practice quality improvement project began in September 
2018. The main objectives were:  
(1) To utilize a screening protocol for metabolic syndrome abnormalities in patients 
treated with atypical antipsychotics in an inpatient psychiatric hospital. 
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(2) To increase the monitoring for metabolic syndrome by participants as evidenced by 
the increased number of laboratory testing (HgA1c and Lipids).  
(3) To increase healthcare providers’ awareness about MetSyn and adverse effects of 
SGAs 
In the initial planning process, a meeting with the clinical director and chief medical 
officer at the behavioral health hospital was held to discuss and determine the need of developing 
and implementing a protocol for metabolic syndrome monitoring for a patient treated with 
atypical antipsychotic medications.  
The project proposal was reviewed and approved in September 2018 by the management 
of the behavioral hospital. After thorough research of the evidence-based literature, a protocol for 
metabolic syndrome monitoring was developed by the author of the project based on ADA and 
APA guidelines (ADA, 2004).   
The data collected after the project was implemented was organized into a Microsoft 
Excel spreadsheet and then entered into IBM-SPSS (Statistic Package for the Social Science) 
statistics software. Qualitative data was used to assess the effectiveness of the implementation of 
the protocol in the hospital. During the information session with prescribers, a survey was 
offered with three closed-ended questions and two open-ended questions to assess their 
awareness about screening for metabolic complication in patients treated with SGAs.  
The descriptive variables and demographic data were analyzed by calculating summary 
means and standard deviations for continuous variables. For this project, Microsoft Word and 
Microsoft Office Excel were used for the tables and spreadsheets. Intention-to-treat analysis was 
used to evaluate by comparing the percentage of baseline parameters recorded in the chart prior 
to the intervention and during the intervention. Categorical variables were analyzed by 
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calculating frequencies and percentages, using the t-test. Statistical analysis to compare data in 
both audits (at the beginning and end of the monitoring period) were performed using paired-
samples t-test.  
The cost of planning, piloting, and implementation of this project was minimal until the 
final incorporation of the metabolic syndrome monitoring protocol into the patients’ medical 
charts. This author developed a metabolic monitoring protocol based on ADA and APA 
recommendation guidelines in collaboration with the management of the hospital using 
practicum hours. 
For the protocol to be created and implemented, estimated resources include a part-time 
employee equivalent (PTEE) for project coordinator position for four months. Additional cost 
included $2,200 for materials, supplies, travel, food, etc. The budget for the project is shown in 
Table 6. There was no funding for this project. Following the time analysis (Appendix E), a chart 
was developed (Fig. 2) to identify major milestones and when these were achieved. The project 
started with an assessment of the project site during September of 2018 and was completed in 
April 2019. 
 Results 
Informational sessions were held by the DNP student for nurses and mental health care 
prescribers to describe the screening protocol. Participants included in the informational sessions 
were eight psychiatrists, twelve nurses, one psychiatric mental health nurse practitioner, and the 
chief nursing officer. A copy of the APA guidelines for metabolic screening, along with the 
modified protocol for monitoring for MetS was provided regarding the metabolic syndrome 
intervention. The informational sessions were held at various times and days over a three-week 
period in the effort to capture all involved health care professionals. 
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At the beginning of the intervention phase, an educational session was held for 
psychiatric providers and nurses based on the literature search and best evidence-based practices, 
and they were familiarized with a screening protocol based on ADA and APA guidelines 
(Appendix C). After this information session, a survey was offered to the prescribers and staff 
nurses to obtain qualitative data about their experience working with SGAs and testing for 
metabolic complications. The survey that was offered to the health care providers after the 
educational session was used to assess individual knowledge of metabolic complications in a 
patient treated with SGAs and ADA/APA guideline’s recommendations. 
The short survey included three closed-ended questions with two open-ended questions 
where the participants could answer with their personal response. The response rate from 
psychiatrists was very low. Only three of all nine (33.3 percent) agreed to complete the survey. 
The three psychiatrists that agreed to complete the survey after taking part in the informational 
sessions answered that they were familiar with the guidelines and are following ADA guideline’s 
recommendations for monitoring for metabolic complications in patients treated with SGAs. 
Those were the first two questions from the survey. Question three asked, “Who has the 
responsibility to screen for metabolic abnormalities?” Two of the psychiatrists answered that this 
is the responsibility of the psychiatrist because he or she prescribes the medications, but mostly 
in outpatient settings. One psychiatrist answered that the responsibility is in conjunction with the 
primary care provider (PCP). The fourth question asked what they think “are some barriers for 
screening…”. The answers for this question were: “Patients are seeing a mental health provider 
and PCP separately”, “Separate payment and billing the insurance twice for the same lab's tests”, 
“Frequent exacerbation of symptoms that require inpatient hospitalizations”, and “Unavailable 
documentation of the test results”. Question five asked for participants opinion “If a screening 
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protocol for metabolic syndrome.” placed in the patient record would improve the rate of testing. 
All three psychiatrists agreed that this will be “helpful”.  
For the remaining six psychiatrists that did not complete the survey, the DNP student 
does not have information about their refusal. The response from the nursing staff was better. Ten 
RNs completed the survey with an average score of eighty-three percent with an SD of 24.9. 
Seven nurses that completed the survey voiced the opinion that ADA guidelines mainly 
concerned the psychiatrists and they are willing to monitor patients’ blood pressure, weight, 
BMI, and waist circumference if these parameters were part of the patients’ paperwork. 
            The patients’ medical charts from the three adult units were reviewed by the DNP student 
and the first thirty eligible patient’s charts that met the criteria were selected. The criteria were: 
age eighteen years and above, and treated with at least one SGAs that had been started in the past 
thirty days. 
The chart audit and review were conducted weekly for ten weeks to track the percentage 
of baseline monitoring tests ordered before and after the protocol had been implemented. Nurses 
were involved in collecting these measurements (weight, BMI, and blood pressure). A 
cumulative summary statistic, the average number of screening measures completed at pre- and 
post-screening protocol placement, was used. 
The family and personal history were recorded for all thirty of the selected patients (100 
percent), blood pressure was recorded for twenty-seven patients (90 percent), and weight was 
recorded for twenty-nine patients (96. 7 percent). BMI was one of the three parameters that had 
been regularly monitored and documented on admission. These three assessments are part of the 
admission paperwork and are performed for every patient admitted to the hospital, no matter 
what medications he or she was treated with.  
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Six of the patients (20 percent) treated with SGAs had HgA1C and eight of them (26.7 
percent) had fasting lipid profile obtained prior to starting SGAs. Surprisingly, not one of the 
patient’s measurements of waist circumference was done. Seventeen of the patients (56.7 
percent) had a BMI of twenty-seven and greater on admission and only four of them (23.5 
percent) had glucose and lipid levels ordered for them prior to starting treatment with SGAs. 
Only three of the seven attending psychiatrists that had been treating these patients ordered the 
blood test prior the interventions, and from these three psychiatrists, one ordered 66.7 percent of 
HgA1C and 62.5 percent of the lipid tests.  
After the screening protocol had been placed in patients’ charts, the final analysis with a 
paired sample t-test demonstrated that the HgA1c tests that had been ordered after implementing 
the protocol (M = .33, SD = .48), t = 3.808, p <.0) increased slightly compared to the pre-
intervention HgA1c tests that had been ordered (M= .20, SD= .40), t = 2.693, p <.01).  The 
results are shown in Table 7.1 and Table 7.2. Prior to the intervention, only three psychiatrists 
(37.5%) ordered 20% of HgA1c tests. After the screening protocol was placed the number of 
psychiatrists that order the test increase to five (62.5%), and the percentage of HgA1c test that 
has been ordered increase to 33%. The same tendency was observed in ordered lipid tests also. 
The post-intervention lipid tests were slightly higher (M= .30, SD= .47), when compared with 
the pre-intervention lipid tests (M =.26, SD=44), t=3.525, p<.01).  The results are shown in 
Tables 8.1 and 8.2. Three of the psychiatrists (37.5%) ordered 26 % of fasting lipid tests prior to 
the interventions; after the interventions, five psychiatrists (62.5%) ordered 30% of lipids tests. 
More than 50% (16) of the patients have been ordered HgA1c test and fasting lipids test.  
 
 
PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME   
31 
 
                                                 Interpretation/Discussion 
Assessing patients for antipsychotic-associated metabolic disturbances and existing 
metabolic pathology or elevated risk factors can influence medications’ choice and follow-up 
treatment plans. The data analysis shows that fasting blood glucose (FBG), Hg1AC and lipids 
testing remain low even post interventions. The ADA and APA guidelines recommended the 
FBG, weight, waist circumference, blood pressure, and fasting lipids to be performed for every 
patient who is treated with SGAs before the treatment with SGAs is initiated, at six weeks, at six 
months, at twelve months, and at least annually thereafter. However, the data from the project 
showed that if these tests are not incorporated in the existing hospital documentation, they are 
not performed regularly.  
Blood pressure, weight, and BMI were recorded in higher percentages due to the fact that 
they were part of the admission assessment. Measuring waist circumference was not part of the 
admission assessment and was not recorded at all. This indicator was not measured after the 
implementation of the screening protocol. Slightly increased rates for Hg1AC and lipids testing 
after the screening protocol was implemented show that efficient metabolic monitoring requires 
an approach focused on educating psychiatrists and medical staff, and developing a system for 
recording the data and defining responsibility for these tasks. 
Barriers to Screening and Monitoring 
Understanding causes for suboptimal metabolic screening in patients receiving atypical 
antipsychotic medications could provide valuable clues on how best to solve this problem. 
Overcoming the barriers to metabolic monitoring is an important aspect of process improvement 
and is directly related to the patient’s outcome as it is shown in Fig. 3. 
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Patient Barriers. Patient-related issues are persistent psychotic symptoms such as paranoia and 
mania, and an alteration in cognition, which can make the patient less compliant with testing no 
matter is her or she in-patient or outpatient. The access and affordability to medical care are also 
barriers along with non-compliance with medical treatment (Gill, 2012). The impaired judgment 
that most of the patients with a chronic mental disorder have do not allow them to recognize and 
acknowledge the metabolic symptoms and to seek medical help.  
Providers’ Barriers. Cohn and Sernyak (2006) suggest that insufficient medical knowledge 
about the additive burden of cardiometabolic complications and not enough emphasis on the 
patient’s medical needs from mental health providers are some of the reasons monitoring 
guidelines are not implemented in mental health settings. However, this does not seem to be 
supported by evidence. A survey conducted in 2007 by Suppes et al. on five hundred US 
psychiatrists found that 97% of them were familiar with the metabolic syndrome abnormalities, 
but only 78% monitored the weight of the patients, only 69% monitored glucose levels, 61% 
monitored lipid levels, 52% monitored blood pressures and 16% monitored HgA1c (Mitchell, 
2011).  
The lowest percentage of monitoring among metabolic syndrome parameters was waist 
circumference. Alberti et al. (2005) suggest that prescribers may not be aware of the importance 
of waist circumference as a strong independent predictor of cardiovascular disease. Limited 
medical resources for patients with severe mental illness have been blamed, as well as a lack of 
time and a shortage of staff to perform these procedures (Gill, 2012). Many psychiatric care 
providers do not assess patients for medical issues and do not order tests because of a lack of 
time, resources, or a lack of consideration regarding the importance of waist circumference 
(Mitchell, 2011).  
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There is an ongoing debate in regards to where the responsibility lies for monitoring 
metabolic abnormality in psychiatric patients receiving SGAs. Does this obligation fall on the 
primary care physician or on the practitioner who actually prescribes the medications (i.e., the 
psychiatrist)? Additionally, who should follow up on abnormal cardiometabolic screening 
results? Some authors claim that this is not strictly the psychiatrist’s responsibly, as long as they 
delegate the task and the tests were performed (Cohn, 2006).  
In general, guidelines are very difficult to implement, not only due to a lack of resources 
and/or time but also because of low organizational support, clinicians’ resistance to change, 
concerns over the quality of the guidelines, and lack of ownership (Mitchell, 2011). 
System Barriers. Overwhelming evidence exists that patients with psychiatric diagnoses receive 
an inferior quality of medical care, including follow-ups for metabolic syndrome and diabetes 
care (Mitchell, 2011). The fact that these patients have to see a primary care provider and a 
mental health provider separately complicates the issue. Insurance coverage could also be a 
serious barrier, in terms of not covering some tests, the newest antipsychotic medications with 
the fewest metabolic complications, or limiting the number of health care providers and 
consultants.  
As the SGAs that mental health providers prescribe increase vulnerability to metabolic 
syndrome, these providers need to be able to diagnose, refer for a medical consult or treat 
metabolic syndrome complications associated with these medications (Parks, 2011). The largest 
controlled study, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), found 
that 88% of the patients with dyslipidemia were untreated, as were 62% with hypertension and 
38% with diabetes (Meyer et al. 2005; Correll et al. 2007). Obviously, it is imperative that the 
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mental health provider assumes responsibility for ensuring appropriate medical management and 
collaborates with the primary care provider in regards to these issues.   
                                                              Conclusion 
Cardiometabolic syndrome remains a serious concern among patients who are treated 
with atypical antipsychotic medications. There is overwhelming evidence-based data that the 
majority of these medications cause significant weight gain, dyslipidemia, hyperglycemia, and 
increased glucose levels that can lead to diabetes. Despite metabolic monitoring guidelines, there 
is still a gap in the monitoring of metabolic syndrome of all individuals on SGAs (Velligan et al., 
2011). Implementation of screening protocols for monitoring and early detection of metabolic 
syndrome abnormalities could decrease the risk of developing those abnormalities and decrease 
morbidity and mortality of the patients receiving atypical antipsychotics.  
This quality improvement project and the implementation of the monitoring protocol for 
cardiometabolic monitoring was successful in increasing the number of baseline relevant testing 
orders for a lipid panel and hemoglobin A1c in the selected patients treated with SGAs. Despite 
the improvement, however, the rates of monitoring for some metabolic parameters remained low 
(i.e., waist circumference). Staff nurse participants demonstrated improved knowledge about the 
metabolic disturbances in patients treated with SGAs and willingness to collaborate with 
psychiatric prescribers regarding metabolic screening. Some of the psychiatrists found the 
metabolic screening protocol somewhat helpful for their practices. The basic screening protocol 
incorporated into the patient medical record and brief staff education has potential to increase 
knowledge of the staff of metabolic disturbances in patients treated with SGAs and improve 
medical staff adherence to guideline recommendations, as well as improve overall patient 
outcomes. 
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Appendix A 
                                                                           
 Informational Session  
The author of the quality improvement project provided mental health care providers with 
the following information: 
1. The significance of metabolic screening for patients treated with atypical 
antipsychotic medications; statistics. 
2. The ADA and APA monitoring guidelines recommendation for metabolic 
monitoring of patients who are treated with SGAs. 
3. A handout with risk factors and metabolic syndrome parameters that need to be 
considered. 
4. A handout with the proposed monitoring protocol base on ADA and APA’s 
guidelines (2004). 
5. Overview of the quality improvement project.  
6.         Survey for psychiatric providers about their experience with SGA’s and screening 
for metabolic syndrome. 
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                                                  Appendix B 
Psychiatric Care Providers Survey 
This questionnaire is part of the student quality improvement project:  IMPLEMENTING 
A PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME IN PATIENTS 
PRESCRIBED ATYPICAL ANTIPSYCHOTICS and all questions related to your care approach 
in the management of patients on second-generation antipsychotic medications (SGAs).  The 
information provided by you is strictly confidential and will be seen by the DNP student and 
Project Committee. You and your practice will not be identified in any reports or publications 
that may result from this project.                                 
1. Are you aware of the specific National Cholesterol Education Program metabolic 
syndrome diagnostic criteria? 
Yes……………………………………………. 
No……………………………………………. 
2. Do you consider monitoring for metabolic abnormalities (weight, BP, Lipid profile, 
Fasting glucose or Hgb A1C, and waist circumference) when prescribing atypical 
antipsychotics (SGAs) and how often? 
Yes…………………………………………… 
            No…………………………………………… 
            How often………………………………. 
 
3. Who has the responsibility to screen for metabolic abnormalities in a patient treated with 
SGAs?............................................................................................... 
……………………………………………………………………………………………… 
……………………………………………………………………………………………… 
4. What do you think are some barriers for screening for metabolic syndrome in patients on 
SGAs?.................................................................................................................................... 
……………………………………………………………………………………………… 
……………………………………………………………………………………………… 
5. Do you think placing a screening protocol for metabolic syndrome in the patient’s chart 
would improve the rate of monitoring for patients on SGAs therapy? 
Yes………………………………………. 
No………………………………………… 
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Appendix C 
Metabolic Monitoring Protocol 
 Your patient is on the following atypical antipsychotic: 
___ aripiprazole (Abilify)                ___ olanzapine (Zyprexa) 
                             ___ asenapine (Saphris)               ___ paliperidone (Invega) 
                             ___ clozapine (Clozaril)                ___ quetiapine (Seroquel) 
                             ___ iloperidone (Fanapt)             ___ risperidone (Risperdal) 
                             ___ Lurasidone (Latuda)              ___ ziprasidone (Geodon)   
 Per ADA/APA guidelines, the following monitoring parameters/labs are recommended 
when a new atypical antipsychotic is started:  
❖ Personal and Family History of obesity, diabetes, dyslipidemia, 
hypertension, cardiovascular disease 
❖ Weight 
❖ Fasting Plasma Glucose 
❖ Waist circumference 
❖ Hemoglobin A1c 
❖ Blood Pressure 
❖ Fasting Lipid Profile 
 For patients continuing previous atypical antipsychotics, please refer to following 
monitoring parameters/labs (Based on the APA/ADA Guidelines). 
 
 Baseline 4 Weeks 8 Weeks 12 Weeks Quarterly Annually 
Personal/Family History       x           x 
Weight (BMI)       x      x       x        x        x       x 
Waist Circumference       x           x 
Blood Pressure       x          x        x 
Fasting Plasma Glucose       x          x        x 
Fasting Lipid profile       x          x        x* 
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association 
for the Study of Obesity, Consensus Development Conference on antipsychotics drugs and obesity and diabetes. Diabetes Care 2004; 598-601 
*Fasting Lipid Profile should be monitored every five years unless significant abnormalities are present. If present, 
monitor annually. 
 ATP III Criteria for Clinical Identification of Metabolic Syndrome 
                             Risk Factors                               Defining Level 
Abdominal Obesity 
• Men 
• Women 
Waist Circumference 
• >102 cm (>40 inches) 
• >88 cm (>35 inches) 
Triglycerides ≥150 mg/dl 
HDL Cholesterol 
• Men 
• Women 
 
• <40 mg/dl 
• <50 mg/dl 
Blood Pressure ≥ 130/85 mmHg 
Fasting Glucose ≥ 110 mg/dl 
If you have any questions, please contact: 
Name: _____________________________________       Extension: ___________________ 
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                                                                          Appendix D 
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Appendix E 
Time Analysis: 
1. Assessment of the needs: September 2018 
2. DNP Project approvals: October 2018 
3. Meeting with clinical director and staff mental health prescribers to familiarize 
them with the project: September/October 2018 
4. Data collection; first patient charts’ audit; implementing of the protocol for 
monitoring of metabolic abnormalities: October 2018 
5. Weekly char audit; final data collection: November 2018 through January 2019 
6. Analysis of the data: February 2019 
7. Project competition: March 2019 
8. Final report and presentation: May 2019        
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Table 1 
Core Criteria for Diagnosing Metabolic Syndrome¹ 
Central obesity                            Waist circumferenceª- ethnicity-specific 
                                                     plus, any two of the following: 
 
Raised triglycerides                     ≥ 1.7 mmol/l (150 mg/dl) or 
                                                     specific treatment for this lipid abnormality 
 
Reduces HDL-Cholesterol          <1.03 mmol/l (40 mg/dl) in male 
                                                     <1.29 mmol/l (50 mg/dl) in female or 
                                                     specific treatment for this lipid abnormality 
 
Raised Blood Pressure                Systolic: ≥130 mmHg 
                                                    or Diastolic: ≥ 85 mmHg 
                                                    or treatment of previously diagnosed hypertension 
 
Raised Fasting Plasma                Fasting plasma glucose ≥ 5.6 mmol/l (100 mg/dl) 
Glucoseᵇ                                      or previously diagnosed with Type 2 diabetes 
                                                    if >5.6 mmol/l or 100 mg/dl, oral glucose tolerance test   
                                                    strongly recommended but is not necessary to define     
                                                    presence of the syndrome        
                                                          
1.Adopted from International Diabetes Federation- metabolic syndrome worldwide definition 
ª If body mass index is > 30 kg/m² then central obesity can be assumed, and waist circumference 
does not need to be measured. 
ᵇ In clinical practice, impaired glucose intolerance is also acceptable, but all reports of the 
prevalence of the metabolic syndrome should use only the fasting plasma glucose and presence 
of previously diagnosed diabetes to assess this criterion. 
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 Table 2 
Atypical Antipsychotics side effects¹ 
       Weight       Dyslipi      DM     EPS    Prolactin    Sedation    QT-interval 
                     gain  demia                   increase                      prolongation 
 
Amisulpride           +       −           +          +          +++         −                  − 
Aripiprazole           −       −           −          +/−        −         +                  − 
Asenapine           +/−      +/−           −           − −        ++                  − 
Clozapine           +++            ++          +++        −          −        +++      + 
Olanzapine           +++      ++           ++         −           −        +++      − 
Quetiapine            ++       +           ++         −  −         ++      − 
Risperidone            ++      +/−           ++         +  +++          +                  ++ 
Ziprasidone            +/−      −            −          −  +           −       ++ 
+++ high incidence; ++ moderate incidence; + low incidence; − very low incidence.  
1. Adapted from American Diabetes Association/American Psychiatric Association, 2004; De 
Nayer et al., 2005; Cohn and Sernyak, 2006; De Hert et al., 2006; Tschoner et al., 2007; Leucht 
et al., 2009). 
EPS = extra-pyramidal symptoms. 
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Table 3 
SWOT Analysis 
                                                   STRENGTHS                                               WEAKNESSES 
INTERNAL                   -Hardworking and dedicated staff       -No current metabolic 
                                       -Families involved with                         syndrome monitoring 
                                        patient care                                            protocol 
                                       -The staff welcomes new projects        -Inconsistencies following 
                                       -Hospital management                           ADA/APA guidelines for 
                                        welcome nursing and advanced            metabolic screening in 
                                        practice nursing students                      patients on SGAs 
                                                                                                     -Short hospital stays 
 
                                                    OPPORTUNITIES                                         THREATS 
            EXTERNAL                 -Hospital welcome and provide          -Psychiatrists resistant to 
                                                   projects for practice                             changes 
                                                   improvement                                      -Psychiatrists’ mistrust of 
                                                  -Administration and                             advanced practice 
                                                   management keep                               nursing role 
                                       communication lines open                 -Needs for corporate  
                                                  -Administration and                             management  
                                       management supportive of                 approval      
                                      the project 
                                      -Metabolic monitoring 
                                       protocol can be used as a 
                                       part of the screening process 
 
ADA- American Diabetes Association 
APA-American Psychiatric Association 
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Table 4 
Monitoring Protocol for Managing Individuals with Normal Baseline Values at the Start              
of an Episode of Care¹ 
 
                                   Baseline        6 weeks (if             12 weeks (if               At least annually 
                                                         starting drug           staring drug               thereafter 
                                                         treatment)              treatment) 
 
Medical history             X 
Weight/waist/BMI         X                    X                            X                               X 
Blood pressure               X                    X                           X                               X 
Fasting glucose              X                    X                           X                               X 
Fasting lipids                 X                    X                           X                                X 
Lifestyle advice             X                    X                           X                                X 
1.Adopted from De Hert, 2011. 
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Table 5 
Patients Data Analyses 
Population Descriptors                             Pre-intervention                     Post-intervention 
                                                                    N = 30                                       N = 30 
 
Sex:   -male                                                20 (66.7%) 
         -female                                              10 (33.3%) 
Age (years)                                                 37.53 
Length of stay (days)                                  20.73 
Race:  -White                                              21 (70%) 
           -Africal American                            8 (26.6%) 
           -Other                                               1 (3.3%) 
Comorbidities: 
           -Diabetes                                          6 (20%) 
           -Hypertension                                   8 (26.7%) 
           -Hyperlipidemia                               4 (13.3%)   
           -Obesity                                           17 (56.7%)  
           -ADHD                                            7 (23.3%) 
Weight                                                        29 (96.7%)                              29 (96.7%) 
Body mass index                                        28 (93.3%)                               28 (93.3%) 
Waist Circumference                                  0                                               0 
Blood pressure                                           27 (90%)                                  27 (90%) 
Fasting Blood Glucose                               6 (20%)                                    10 (33.3%) 
     (HgA1c) 
Lipid Panel                                                 8 (26.7%)                                  9 (30%) 
ADHD-Attention Deficit Hyperactive Disorder 
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Table 6 
Budget 
                                        Annual Cost to implement the Project 
                                                        2018                              2019 
Gas                                                           $ 100                              $50 
Paper                                                         $50                                $50 
Pens, pencils, markers                              $60                                $40 
Making copies                                          $500                              $100 
Meetings/materials                                   $100                              $50 
Miscellaneous                                          $100                              $500 
Total                                                        $ 910                              $790 
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Table 7.1.  
One-Sample Statistics of HgA1c Testing prior to and after Interventions 
                               N              Mean            Std.Deviation         St. Error Mean 
HgA1c ª                  30             .2000                 .40684                 .07428 
postHgA1c ᵇ            30            .3333                 .47946                 .08754 
ª HgA1c prior interventions 
ᵇ postHgA1c – HgA1c after the interventions 
 
 
 
Table 7.2. 
One -sample Test of HgA1c Testing prior to and after Interventions 
                                                                       Test Value = 0 
                                                                                           95% Confidence Interval of the 
                                                                                                         Difference 
                           t                df           Sig. (2-tailed)      Mean               Lower            Upper 
                                                                                      Difference 
HgA1cª             2.693         29             .012                    .20000            .0481              .3519 
postHgA1cᵇ      3.808         29             .001                    .33333            .1543              .5124 
ª HgA1c prior interventions 
ᵇ postHgA1c – HgA1c after the interventions 
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Table 8.1. 
One-Sample Statistics of Lipids Testing Prior and after Interventions 
                                     N                 Mean            Std. Deviation          Std. Error Mean 
Lipidsª                          30               .2667               .44978                     .08212 
postLipids ᵇ                  30               .3000               .46609                     .08510       
ª Lipids prior interventions 
ᵇ postLipids – Lipids after the interventions 
 
 
 
 
Table 8.2. 
One-Sample Test of Lipids Testing Prior and after Interventions 
                                                                       Test Value = 0 
                                                                                            95%  Confidence Interval of the 
                                                                                                         Difference 
                                 t           df          Sig. (2-tailed)      Mean             Lower       Upper 
                                                                                      Difference 
Lipidsª                    3.247      29           .003                  .26667             .0987          .4346 
postLipidsᵇ             3.525      29           .001                  .30000             .1260          .4740 
ª Lipids prior interventions 
ᵇ postLipids – Lipids after the interventions 
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Fig.1. The Donabedian Model: Structure- Process-Outcome 
 
 
 
 
 
 
 
 
                                                                         
    
Structure/ Inputs 
How is the care organized? 
The stable elements which makeup the 
system; patients, equipment, supplies, 
training, environment 
 
Process/Steps 
What is done? 
What happens in the interactions? 
Coordination, physician orders 
Outcome/Outputs 
What happens to the patient’s 
health? 
Clinical outcomes, functional 
status, cost 
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Task Jun  
 
Jul Aug Sep Oct Nov Dec 
 
Jan Feb Mar Apr 
 
May 
 2018       2019     
The topic finalized 
Researched information and 
review the literature 
  
  X 
           
Gained permission to 
conduct the project; wrote 
the project prospectus; wrote 
the protocol 
  
 X 
  
 X 
 
 X 
        
Secure the necessary 
supplies; gained final 
approval from Southcoast 
Behavioral Health 
   
 X 
 
 X 
        
Final meeting with a medical 
director  
; meeting with prescribers 
(psychiatrists, NPs)  
Chart Review of eligible 
patients 
     
      
X 
 
      
X 
       
Intervention: 
Implementing the protocol 
begin 
    
     
 X 
      
X  
       
 X 
       
     
Weekly chart audit after the 
protocol was implemented 
and information collection 
starts; continuous 
implementation of metabolic 
protocol monitoring 
        
   X 
 
   X  
 
   X 
  
Analyze data and write a 
project report 
         
    
  X 
 
 X  
Presenting the final report to 
the clinical director and staff 
of the hospital 
              X 
 
Fig.2. Timeline 
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  Family Barriers                        Clinical Team Barriers              Structural/Process-of-care 
                                                                                                                 Barriers 
-Emotional distress          -Inadequate communication skills    -Clinician turnover          
-Uncertainty about           -Lack of interest                                -Time constraints 
patient’s preferences        -Inadequate attention to emotional    -Lack of timely/regular 
-Personal desires about       and moral considerations                  communication 
goals for the patient                                                                    -Failure to include key 
-Intrafamily conflict                                                                     members of the family 
-Distrust of clinicians                                                                   or of the team 
 
                
                       Ideal Clinical Team                          Ideal Structure/Process of Care 
                -Accept diverse goals of care             -Early and timely communication 
                -Effectively communicate                  -Clinician continuity 
                 prognostic information                      -Convenient space for meetings 
                -Present treatment options                  -Multidisciplinary involvement 
                 without undue bias 
                -Provide emotional and moral 
                 support 
                  
                   
                        Good outcomes                                Bad outcomes 
                -Patient-centered decisions                 -Non-patient centered decisions 
                -Appropriate resource use                   -Adverse psychiatric sequelae for 
                                                                             surrogates 
                                                                            -Inappropriate resource use 
 
 
 
Fig.3. The Donabedian Model: Barriers; outcomes            
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